��������

Manuel Sturzbecher-Hoehne has extensive work experience in the field of radiopharmaceutical development and project research. Manuel currently holds the position of Head CMC and Radiopharmaceutical Development at Ariceum Therapeutics, starting in 2022. Prior to this, Manuel worked at OctreoPharm Sciences GmbH from 2016 to 2021, where they held the positions of Radiopharmaceutical Development Site Manager and CMC Manager. From 2010 to 2015, they worked at Berkeley Lab, where they served as a Project Scientist and Post-doctoral Research Associate, focusing on the research and development of actinide decorporation agents and investigating biochemical pathways of radionuclides.

Manuel Sturzbecher-Hoehne completed their education in a chronological order. Manuel began their academic journey at Gymnasium Oschersleben from 1991 to 1999. However, no specific degree or field of study is provided for this period. Next, they attended Technische Universität Dresden from 2000 to 2005, where they obtained a Diploma in Food Chemistry. After this, Manuel pursued further education at ETH Zürich, where they attained a PhD in Chemistry from 2005 to 2009. Lastly, in 2019 to 2020, they attended ESMT Berlin and completed the Executive Transition Program in General Management.